

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-26. (canceled)

27. (previously presented) A method for the treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody wherein said antibody is raised against a protofibril comprising an A $\beta$ -Arc peptide selected from the group consisting of A $\beta$ 39-Arc (Amino Acids 1-39 of SEQ ID NO:1), A $\beta$ 40-Arc (Amino Acids 1-40 of SEQ ID NO: 1), and A $\beta$ 42-Arc (SEQ ID NO: 1), wherein said antibodies bind to arctic and wild-type A $\beta$  peptides in protofibril conformation.

28-43. (canceled)

44. (previously presented) A method for the treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody, wherein said antibody is raised against a protofibril comprising an A $\beta$ -Arc peptide selected from the group consisting of A $\beta$ 39-Arc (Amino Acids 1-39 of SEQ ID NO:1), A $\beta$ 40-Arc (Amino Acids 1-40 of SEQ ID NO:1), A $\beta$ 41-Arc (Amino Acids 1-41 of SEQ ID NO:1), A $\beta$ 42-Arc (SEQ

ID NO:1), and combinations thereof, wherein said antibodies bind to arctic and wild-type A $\beta$  peptides in protofibril conformation.

45. (previously presented) The method according to claim 44, wherein said protofibril further comprises an A $\beta$  peptide having a mutation selected from the group consisting of the Dutch, Flemish, Italian, Iowa mutations, and combinations thereof.

46-48. (canceled)

49. (previously presented) The method according to claim 44, wherein said antibody is monoclonal.

50. (previously presented) The method according to claim 44, wherein said antibody is human or humanized.

51. (currently amended) A method for the treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody, wherein said antibody is raised against a composition comprising a protofibril comprising an A $\beta$ -Arc peptide selected from the group consisting of A $\beta$ 39-Arc (Amino Acids 1-39 of SEQ ID NO:1), A $\beta$ 40-Arc (Amino Acids 1-40 of SEQ ID NO:1), A $\beta$ 41-Arc (Amino Acids 1-41 of SEQ ID NO:1), A $\beta$ 42-Arc (SEQ ID NO:1), and combinations thereof, wherein said antibodies bind to arctic and wild-type A $\beta$  peptides in protofibril conformation.

52. (previously presented) The method according to claim 44, wherein said protofibril further comprises an A $\beta$  peptide having a Dutch mutation.

53-56. (canceled)

57. (previously presented) The method according to claim 44, wherein said A $\beta$ -Arc peptide is A $\beta$ 39-Arc (Amino Acids 1-39 of SEQ ID NO:1).

58. (previously presented) The method according to claim 44, wherein said A $\beta$ -Arc peptide is A $\beta$ 40-Arc (Amino Acids 1-40 of SEQ ID NO:1).

59. (previously presented) The method according to claim 44, wherein said A $\beta$ -Arc peptide is A $\beta$ 41-Arc (Amino Acids 1-41 of SEQ ID NO:1).

60. (previously presented) The method according to claim 44, wherein said A $\beta$ -Arc peptide is A $\beta$ 42-Arc (SEQ ID NO:1).

61. (new) The method according to claim 51, wherein said antibody is monoclonal.

62. (new) The method according to claim 51, wherein said antibody is human or humanized.

63. (new) The method according to claim 51, wherein said protofibril further comprises an A $\beta$  peptide with a mutation selected from the group consisting of the Dutch, Flemish, Italian and Iowa mutations.

64. (new) The method according to claim 51, wherein said A $\beta$ -Arc peptide is A $\beta$ 39-Arc (Amino Acids 1-39 of SEQ ID NO:1).

65. (new) The method according to claim 51, wherein said A $\beta$ -Arc peptide is A $\beta$ 40-Arc (Amino Acids 1-40 of SEQ ID NO:1).

66. (new) The method according to claim 51, wherein said A $\beta$ -Arc peptide is A $\beta$ 42-Arc (SEQ ID NO:1).

67. (new) The method according to claim 51, wherein said A $\beta$ -Arc peptide is A $\beta$ 41-Arc (Amino Acids 1-41 of SEQ ID NO:1).